ClinConnect ClinConnect Logo
Search / Trial NCT03865693

Effects of Pain Scrambler Therapy for the Alterations of Cerebral Blood

Launched by HANGANG SACRED HEART HOSPITAL · Mar 5, 2019

Trial Information

Current as of April 24, 2025

Unknown status

Keywords

Burn Pain Scrambler

ClinConnect Summary

The groups (scrambler therapy and sham therapy) were randomly assigned. All subjects were recruited in scrambler thrapy and sham stimulation. Main study outcomes included group differences in CBV changed and the the relationship between CBV changes and neuropathic pain intensity. These analyses were performed using the same framework of the general linear model, which was repeatedly applied to each voxel with the same coordinates.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Burn patients
  • severe neuropatic pain rated at least 5 on the 10-point numerical rating scale (NRS)
  • Exclusion Criteria:
  • cardiac arrest history
  • history of neurologi disease or brain surgery
  • unstable heart disease or presence of a cardiac pacemaker
  • pain resulting from other causes like as neuromuscular diseases
  • psychiatric disorder
  • diabetes mellitus
  • abnormal renal function
  • contraindication for MRI, or pregnancy.

Trial Officials

Cheong Hoon Seo, M.D.

Principal Investigator

Hangang Sacred Heart Hospital

About Hangang Sacred Heart Hospital

Hangang Sacred Heart Hospital is a prominent healthcare institution dedicated to advancing medical research and patient care. With a strong commitment to innovation and excellence, the hospital serves as a key clinical trial sponsor, facilitating cutting-edge studies that aim to enhance treatment options and improve health outcomes. Equipped with state-of-the-art facilities and a team of experienced researchers and healthcare professionals, Hangang Sacred Heart Hospital prioritizes ethical standards and patient safety in all its clinical trials, fostering collaboration with academic institutions and industry partners to drive meaningful advancements in medicine.

Locations

Seoul, Yeong Deungpo Dong, Korea, Republic Of

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials